Updated Jul 16, 2026
Stenhouse Mark has filed 1 SEC Form 4 filing across 1 company in the last 90 days.

Mark Stenhouse is identified in Phathom Pharmaceuticals, Inc.'s SEC filings as of May 21, 2026. His exact title and role are not specified in the provided context. He appears in the SEC filing context as an insider associated with Phathom Pharmaceuticals, a biotechnology company. Alternative name ordering (e.g., Mark Stenhouse vs. Stenhouse Mark) may appear in different filings. No additional public biographical details are available in this context.
| Role | Insider |
|---|---|
| Notability | 28/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | PHAT | Phathom Pharmaceuticals, Inc. | A — Grant or award | 24.1K | $0.00 |
Mark Stenhouse is identified in Phathom Pharmaceuticals, Inc.'s SEC filings as of May 21, 2026. His exact title and role are not specified in the provided context. He appears in the SEC filing context as an insider associated with Phathom Pharmaceuticals, a biotechnology company. Alternative name ordering (e.g., Mark Stenhouse vs. Stenhouse Mark) may appear in different filings…
1 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Stenhouse Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.